StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.50+0.12 (+3.55%)

Close on Nov 18, 2026Market cap $515.20MP/E –Yield –

Aclaris Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Aclaris Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $8.22M, down 51.0% year over year. For fiscal 2025 it was $7.83M, down 58.2% from the year before. The highest annual figure on record is $31.25M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.83M-58.2%
FY2024Dec 31, 2024$18.72M-40.1%
FY2023Dec 31, 2023$31.25M+5.0%
FY2022Dec 31, 2022$29.75M+340.1%
FY2021Dec 31, 2021$6.76M+4.3%
FY2020Dec 31, 2020$6.48M+53.3%
FY2019Dec 31, 2019$4.23M-31.3%
FY2018Dec 31, 2018$6.15M+265.5%
FY2017Dec 31, 2017$1.68M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.63M-8.3%
Q1 FY2026Mar 31, 2026$2.00M+37.2%
Q4 FY2025Dec 31, 2025$1.30M-85.9%
Q3 FY2025Sep 30, 2025$3.30M-24.1%
Q2 FY2025Jun 30, 2025$1.78M-35.8%
Q1 FY2025Mar 31, 2025$1.46M-39.3%
Q4 FY2024Dec 31, 2024$9.21M-47.6%
Q3 FY2024Sep 30, 2024$4.35M-53.2%
Q2 FY2024Jun 30, 2024$2.77M+48.0%
Q1 FY2024Mar 31, 2024$2.40M-5.1%
Q4 FY2023Dec 31, 2023$17.57M+126.6%
Q3 FY2023Sep 30, 2023$9.28M-51.2%
Q2 FY2023Jun 30, 2023$1.87M+22.3%
Q1 FY2023Mar 31, 2023$2.53M+74.0%
Q4 FY2022Dec 31, 2022$7.75M+416.5%
Q3 FY2022Sep 30, 2022$19.02M+1046.4%
Q2 FY2022Jun 30, 2022$1.53M-16.2%
Q1 FY2022Mar 31, 2022$1.45M-18.2%
Q4 FY2021Dec 31, 2021$1.50M-5.0%
Q3 FY2021Sep 30, 2021$1.66M+14.5%
Q2 FY2021Jun 30, 2021$1.82M-10.9%
Q1 FY2021Mar 31, 2021$1.78M+26.3%
Q4 FY2020Dec 31, 2020$1.58M+44.3%
Q3 FY2020Sep 30, 2020$1.45M+47.4%
Q2 FY2020Jun 30, 2020$2.05M+130.9%
Q1 FY2020Mar 31, 2020$1.41M+11.4%
Q4 FY2019Dec 31, 2019$1.10M-70.2%
Q3 FY2019Sep 30, 2019$983.00K-12.1%
Q2 FY2019Jun 30, 2019$886.00K-75.9%
Q1 FY2019Mar 31, 2019$1.26M+13.0%
Q4 FY2018Dec 31, 2018$3.67M+267.3%
Q3 FY2018Sep 30, 2018$1.12M+63.5%
Q2 FY2018Jun 30, 2018$3.68M–
Q1 FY2018Mar 31, 2018$1.12M–
Q4 FY2017Dec 31, 2017$999.00K–
Q3 FY2017Sep 30, 2017$684.00K–

More Aclaris Therapeutics figures

See a number that looks wrong?